A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementia
Shifu Xiao(Shanghai Jiao Tong University), Raoli He(Fujian Medical University), Benyan Luo(First Affiliated Hospital Zhejiang University), Shengdi Chen(Ruijin Hospital), Yun‐Cheng Wu(Shanghai Jiao Tong University), Wei Zhang(China Pharmaceutical University), Zhonglin Liu(Sun Yat-sen University), Xiaoping Pan(Guangzhou First People's Hospital), Qianhua Zhao(Fudan University), Yong Ji(Nankai University), Yang Lü(Chongqing Emergency Medical Center), Piu Chan(Capital Medical University), Ying Peng(Sun Yat-sen University), Lijun Jiang(Sichuan University), Jun Xu(Northern Jiangsu People's Hospital), Yingjun Ouyang(Guangzhou First People's Hospital), Wenwei Ren(Wenzhou Medical University), Yuying Zhou(Nankai University), Shuzhen Wang(China Pharmaceutical University), Dantao Peng(Chinese Academy of Medical Sciences & Peking Union Medical College), Qihao Guo(Fudan University), Shuai Liu(Shandong Provincial Hospital), Yan Wang(Nankai University), Nan Zhang(Tianjin Medical University General Hospital), Wei Chen(Sir Run Run Shaw Hospital), Xiaowei Liu(Jiangxi Mental Health Center), Yi Li(Baylor College of Medicine), Tao Wang(Shanghai Jiao Tong University), Xiaoping Wang(Shanghai Jiao Tong University), Yan Cheng(Tianjin Medical University General Hospital), Shuhua Li(Beijing Hospital), Chun‐Feng Liu(Soochow University), Lu‐Ning Wang(China-Japan Friendship Hospital), Jianjun Jia(Chinese PLA General Hospital), Qiumin Qu(First Affiliated Hospital of Xi'an Jiaotong University), Zhongxin Zhao(Shanghai Changzheng Hospital), Weixian Chen(Chongqing Medical University), Junjian Zhang(Wuhan University), Yansheng Li(Renji Hospital), Yongtao Zhou(Capital Medical University), Zhen Hong(Fudan University), Yong Yan(The Affiliated Yongchuan Hospital of Chongqing Medical University), Wenyuan Wu(Tongji University), Qinyong Ye(Fujian Medical University), Dongsheng Fan(Peking University), Jincai He(Wenzhou Medical University), Peixian Mao(Capital Medical University), Weihong Kuang(First Affiliated Hospital of Guangzhou University of Chinese Medicine), Qiumei Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Yifeng Du(Shandong University)
Cited by 200
Related Papers
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
|The Lancet|2020|3.7k
Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets
|Signal Transduction and Targeted Therapy|2023|1.3k
Reduced default mode network functional connectivity in patients with recurrent major depressive disorder
|Proceedings of the National Academy of Sciences|2019|865
Evaluation and accurate diagnoses of pediatric diseases using artificial intelligence
|Nature Medicine|2019|710
AAV Vector Integration Sites in Mouse Hepatocellular Carcinoma
|Science|2007|648